Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cancer Research UK aims for £230 million funding in 2004-05:

This article was originally published in Clinica

Executive Summary

Cancer Research UK (CRUK) invested £213m ($392m) in 2003-04 forresearch into cancer and is currently aiming to increase its annual spend by 7.5% - around £229m. So says the UK's leading charity for the promotion of research into the prevention, detection and treatment of cancer in its annual report. So far this year, it is already £20m ahead, says CRUK. Last year's successes include investigating the potential of flexible sigmoidoscopy as a screening tool for bowel cancer, for preventing up to 5,000 cases a year and work to discover the genes that could explain non-hereditary forms of ovarian and breast cancer. It also highlighted its strong support for the National Cancer Research Network, helping to treble the number of patients involved in clinical trials in the UK.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT059409

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel